The reasons why some patients with small-cell lung cancer (SCLC) benefit from chemotherapy and immunotherapy, while others rapidly develop resistance, are still undefined. Despite improved outcomes with platinum-based chemotherapy combined with immune checkpoint inhibitors have been correlated to activation of the inna...
C. De Rosa, Fabio Somma, Luisa Amato et al.· The journal of liquid biopsy· 0 citations
Small cell lung cancer (SCLC) is one of the most aggressive and rapidly progressing forms of lung cancer, characterized by its high proliferative rate and strong tendency to metastasize. Although SCLC initially responds well to platinum-based chemotherapy, resistance typically develops quickly, leaving few effective op...
C. De Rosa, Cristina A. Diaz, J. M. Morillas et al.· Lung Cancer· 0 citations
Liquid biopsy guided anti-EGFR rechallenge therapy is gaining ground as a potential option for patient with refractory metastatic colorectal cancer. However, the identification of potential biomarkers to implement patient's stratification is required. The CAVE-2 GOIM trial investigated the role of rechallenge with cetu...
Davide Ciardiello, G. Martini, L. Boscolo Bielo et al.· The journal of liquid biopsy· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.